跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/jRCTs031240273
jRCTs031240273招募中不适用

Examination of the relationship between prolonging the administration interval of faricimab and anti-Ang-2 effects in nAMD patients

未提供0 个研究点目标入组 57 人开始时间: 2024年8月27日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
不适用
状态
招募中
入组人数
57
主要终点
Switch subjects
研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized Controlled Trial
干预模型
Parallel Assignment
主要目的
Diagnostic Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
50age old over 至 No limit（—）
性别
All

入选标准

  • •General Selection Criteria
  • •Patients who are willing and able to provide signed informed consent.
  • •Patients who are 50 years or older at the time of signing the informed consent.
  • •Patients who are able and willing to attend all scheduled visits and undergo all scheduled tests.
  • •Selection Criteria for the Target Eye
  • •Only one eye will be designated as the target eye. If both eyes are deemed eligible, the eye with the worse BCVA at screening will be selected as the target eye, unless the principal investigator or sub-investigator determines that the other eye is more suitable for the study treatment.
  • •Age-related macular degeneration (nAMD) with subfoveal choroidal neovascularization.
  • •Patients with active lesions affecting the foveal area (such as IRF, SRF) as evaluated by OCT-A or OCT.
  • •Patients with a visual acuity (decimal visual acuity) of 1.0 to 0.05 in the pre-treatment vision test conducted on Day
  • •Patients with sufficiently clear intermediate media and adequately dilated pupils to allow for high-quality color fundus photographs (CFP) and other imaging tests.
  • •Patients who have previously received intravitreal injections of other anti-VEGF drugs (switch patients) with the most recent two injection intervals being 8-12 weeks apart.* *The date on which the attending physician determines that anti-VEGF drug administration is necessary due to disease progression during prior treatment is defined as the "disease activity confirmation date." Ideally, the disease activity confirmation date and the administration date should be the same. If they are on different dates due to clinical reasons, administration should be performed as soon as possible (within 2 weeks). In such cases, the period from the previous administration date to the disease activity confirmation date is considered the "injection interval," and if this interval is 8-12 weeks, the patient can be included in the study.

排除标准

  • •1 General Exclusion Criteria
  • •Patients with a history of severe allergic or anaphylactic reactions to biologics or known hypersensitivity to components of faricimab, mydriatic eye drops, anesthetics, or antibiotics.
  • •Patients with a history or current clinical test findings that contraindicate the use of faricimab or that the principal investigator or co investigator suspects may affect the interpretation of the study results or may increase the risk of complications.
  • •Patients receiving systemic treatment for suspected or active systemic infection.
  • •Patients with poorly controlled hypertension (defined as resting systolic blood pressure over 180 mmHg and or diastolic blood pressure over 100 mmHg). If the first measurement during the screening period exceeds these values, the measurement may be repeated on the same day or on another day during the screening period.
  • •Patients who have had a stroke (cerebrovascular accident) or myocardial infarction within 6 months prior to Day 1
  • •Patients who need to continue to use the following prohibited concomitant drugs or treatments.
  • •Systemic administration of anti VEGF drugs
  • •Systemic drugs known to cause macular edema (e.g., fingolimod, tamoxifen)
  • •Intravitreal administration of anti VEGF drugs (other than faricimab) to the target eye
  • •Intravitreal, periocular (sub Tenon), or habitual local administration of steroids to the target eye
  • •Photodynamic therapy (PDT) to the target eye
  • •Micropulse and local or lattice photocoagulation to the target eye
  • •Vitreous surgery or PRP to the target eye
  • •Kallidinogenase (for improving symptoms of retinal choroidal circulatory disorders)
  • •Other experimental treatments (excluding those with vitamins and minerals)

结局指标

主要结局

Switch subjects

Interval until re administration criteria are met after the induction period (extention from before switching)

Naive subjects

时间窗: W56

administration interval at W56

次要结局

未报告次要终点

研究者

发起方
未提供

相似试验

已完成
不适用
A studyone
JPRN-UMIN000034518ew drug research center, Inc.200
招募中
不适用
ACE study (ACE study)
jRCT103224050764
招募中
不适用
Development and validation of a scale to predict the risk of failure on the first attempt of inserting an intravenous peripheral catheterIntravenous peripheral catheter insertion (inbrengen van een perifere intraveneuze canule)Prediction of difficulty of inserting a peripheral intravenous catheter (voorspellen van de moeilijkheid tijdens het inbrengen van een perifere intraveneuze canule)
NL-OMON27540Catharina Hospital EindhovenMichelangelolaan 25623 EJ Eindhoven2,500
招募中
不适用
NOL study (NOL study)
jRCTs072240066110
招募中
不适用
Sens-AVK-StudyPeripheral arterial occlusive disease, intermittent claudication stages IIa-IIb according to Fontaine/ 1-3
DRKS00033683niversitätsklinikum Heidelberg150